Clinical trials: Idarubicin
Leukemia
Chemotherapy in Treating Children With Recurrent Acute Myeloid Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00003178
- Testing
- filgrastim, cladribine, idarubicin
- Where
- 235 sites in United States, Australia and 5 more
- Volunteers
- 120 people
- Sponsor
- Children's Oncology Group
Acute Myeloid Leukemia (Relapsed/Refractory)
A Phase II Study of Selinexor Plus Cytarabine and Idarubicin in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)
Acute Myeloid Leukemia (AML) is currently treated with chemotherapy by combining several drugs with different ways of inhibiting the cell growth.
- Trial name
- NCT02249091
- Testing
- Selinexor, Idarubicin, Cytarabine
- Where
- 3 sites in Germany
- Volunteers
- 42 people
- Sponsor
- GSO Global Clinical Research BV
Leukemia, Leukemia, Acute
Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL
Based on the pediatric-inspired, PEG-L-asparaginase-intensified and MRD-directed PDT-ALL-2016 protocol, this open-label, one-arm, multi-site trial PDT-ALL-LBL is aimed to evaluate the safety and effect of oral histone deacetylase…
- Conditions
- Leukemia, Leukemia, Acute, Adult Lymphoblastic Lymphoma, Leukemia, Lymphoblastic
- Trial name
- NCT03564704
- Testing
- Dexamethasone, vincristine, Cyclophosphamide
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Acute Myeloblastic Leukaemia
Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years
To reproduce or to improve the index of complete responses of protocol LMA-91 with a similar protocol, decreasing the dose of Idarubicin to try to reduce the deaths in induction
- Trial name
- NCT00464217
- Testing
- ARA-C, Idarubicin, Leucomax
- Where
- 24 sites in Spain
- Volunteers
- 100 people
- Sponsor
- PETHEMA Foundation
Acute Lymphoblastic Leukemia
A Study of Children With Refractory or Relapsed ALL
The main purpose of this study is to find out which form of asparaginase (the native E. coli/Erwinia) or PEG-asparaginase) is more effective during induction treatment for children with acute lymphoblastic leukemia that has come…
- Trial name
- NCT00187083
- Testing
- Topotecan, dexamethasone, vincristine, E. coli Asparaginase, PEG-L-asparaginase, erwinia asparaginase
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- St. Jude Children's Research Hospital
Acute Myeloid Leukemia
Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
This is a phase 1b, dose escalation, study of quizartinib to evaluate the safety profile, the pharmacokinetics, and the recommended dose of quizartinib for subsequent clinical studies of the combination of quizartinib and…
- Trial name
- NCT02834390
- Testing
- Quizartinib, Cytarabine, Idarubicin
- Where
- Japan
- Volunteers
- 7 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Acute Myeloid Leukemia
Gemtuzumab Ozogamicin+Cytarabine vs Idarubicin+Cytarabine in Elderly Patients With AML.Mylofrance 4
Purpose : The main objective of this study is to assess the efficacy and tolerance of the addition of repeated doses of low doses (3mg/m2) of Gemtuzumab Ozogamicin (GO) in addition with standard doses of Ara-C in previously…
- Trial name
- ALFA1401 (NCT02473146)
- Testing
- Gemtuzumab ozogamicin (GO)
- Where
- 21 sites in France
- Volunteers
- 225 people
- Sponsor
- Versailles Hospital
Acute Myeloid Leukemia
A Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid Leukaemia
The main objective of this study is to assess the biological activity of elacytarabine in combination with idarubicin in patients with acute myeloid leukaemia who has failed the first course of a remission-induction treatment…
- Trial name
- NCT01035502
- Testing
- Elacytarabine plus idarubicin
- Where
- 8 sites in United States, France and 2 more
- Volunteers
- 51 people
- Sponsor
- Clavis Pharma
Acute Myeloid Leukemia
Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML
To compare the efficacy and safty of ABC-14 regimen with the traditional "3+7" regimen or AB-14 regimen in the treatment of newly diagnosed acute myeloid leukaemia
- Trial name
- NCT06451861
- Testing
- Chidamide, Venetoclax, azacitidine
- Where
- 13 sites in China
- Volunteers
- 240 people
- Sponsor
- Guangdong Provincial People's Hospital
Acute Myeloid Leukemia
Optimizing Induction Chemotherapy Regimens for ND Elderly AML Patients Who Are Eligible for Intense Chemotherapy
The optimal induction chemotherapy regimen for newly diagnosed elderly AML patients who are eligible for intense chemotherapy is currently not well defined.
- Trial name
- NCT06066242
- Testing
- Different induction chemotherapy regimens
- Where
- China
- Volunteers
- 113 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Acute Myeloid Leukemia
GOELAMS SA4 Study: the Role of Fludarabine in the Treatment of Acute Myeloid Leukemia in the Elderly
In this study, patients were randomly assigned to either receive fludarabine or not (20 mg/m2/d) in addition to induction chemotherapy, consolidation chemotherapy and the 3 subsequent re-induction courses during maintenance.
- Trial name
- NCT00925873
- Testing
- Active comparator (no fludarabine), Experimental (fludarabine)
- Where
- France
- Volunteers
- 303 people
- Sponsor
- French Innovative Leukemia Organisation
Acute Myeloid Leukemia (AML)
Monocentric Phase 1 Study With Escalation of Doses of Tocilizumab in Combination With Chemotherapy (Idarubicin and Cytarabine) in Patients With Acute Myeloblastic Leukemia (AML)
This is a phase 1 dose escalation study testing the addition of an anti-IL6 (tocilizumab) to standard induction chemotherapy for high-risk AML.
- Trial name
- Tocilam (NCT04547062)
- Testing
- Tocilizumab
- Where
- France
- Volunteers
- 12 people
- Sponsor
- Nantes University Hospital
Leukemia, Myeloid, Acute
Safety and Efficacy Study of Idarubicin Dose Intensification to Treat Acute Myeloid Leukemia
The purpose of this study is to determine whether idarubicin dose intensification is safe and effective as a remission induction therapy for acute myeloid leukemia.
- Trial name
- IDAML (NCT01518556)
- Testing
- Idarubicin
- Where
- South Korea
- Volunteers
- 49 people
- Sponsor
- Konkuk University Medical Center
Acute Myeloid Leukemia
Induction, Consolidation and Intensification Therapy for Patients Younger Than 66 Years With Previously Untreated CD33 Positive Acute Myeloid Leukemia (AML)
This is a prospective, open, non-randomized, non-controlled, phase II, clinical trial for treatment of newly diagnosed AML patients, younger than 66 years. Trial is based on: INDUCTION: FLAI + Gemtuzumab-Ozogamicin (FLAI-GO).
- Trial name
- MYFLAI07 (NCT00909168)
- Testing
- FLAIMy - Fluda, Ida, Ara-C, Mylotarg
- Where
- Italy
- Volunteers
- 130 people
- Sponsor
- University Hospital, Udine, Italy
Graft Versus Host Disease, Leukemia
Donor Lymphocytes to Prevent Graft-Versus-Host Disease in Patients With Chronic Myeloid Leukemia
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy used to kill cancer cells. Sometimes the transplanted cells can be rejected by the body's normal tissues.
- Trial name
- NCT00004878
- Testing
- therapeutic allogeneic lymphocytes, cytarabine, fludarabine phosphate
- Sponsor
- Jonsson Comprehensive Cancer Center
Acute Myeloid Leukemia
Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia
This study will examine the appropriate dose and side effects of dasatinib, when it is given with the standard of care chemotherapy for children and adolescents with Acute Myeloid Leukemia (AML).
- Trial name
- NCT02680951
- Testing
- Dasatinib, Fludarabine, Cytarabine
- Sponsor
- Emory University
Leukemia
A Study in Leukemia Patients With Karonudib
The primary objective of this study is to determine safety and tolerability of Karonudib for the treatment of hematological malignancies.
- Trial name
- MAATEO (NCT04077307)
- Testing
- Karonudib
- Where
- 7 sites in Denmark, Serbia and 1 more
- Volunteers
- 50 people
- Sponsor
- Thomas Helleday Foundation
Leukemia, Myeloid, Acute
Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML
This study will evaluate GMI-1271, a specific E-selectin antagonist, in acute myeloid leukemia in combination with standard agents used to treat this disease.
- Trial name
- NCT02306291
- Testing
- GMI-1271, Mitoxantrone, Etoposide
- Where
- 8 sites in United States, Australia and 1 more
- Volunteers
- 91 people
- Sponsor
- GlycoMimetics Incorporated
Leukemia, Monocytic, Acute, Pediatric AML
Treateament of Newly Diagnosed Acute Monocytic Leukemia in Children
This is a multicenter, single arm, prospective, intervention trial. Since cladribine can enhance the biological activity and self-protection of cytarabine, giving cladribine and cytarabine together may kill more cancer cells.
- Trial name
- SCCLG-M5 (NCT05313958)
- Testing
- Cladribine, G-CSF, Cytarabine
- Where
- 9 sites in China
- Volunteers
- 43 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Acute Promyelocytic Leukemia
Treatment of Acute Promyelocytic Leukemia With All-Trans Retinoic Acid (ATRA) and Idarubicin (AIDA)
The purpose of this study is to evaluate the efficacy of all-trans retinoic acid (ATRA) and idarubicin (AIDA) with a dose reduction in patients older than 70 years of age in the remission induction of acute promyelocytic leukemia…
- Trial name
- NCT00465933
- Testing
- AIDA
- Where
- 2 sites in Spain
- Sponsor
- PETHEMA Foundation